Biography
Richard Weinshilboum, M.D. studies pharmacogenomics — the role of inheritance and individual variation in DNA sequence or structure in drug response. The goal is to develop safer and more effective drug therapy to treat diseases that range from cancer to depression. Dr. Weinshilboum's research program utilizes genomic techniques that include genome-wide association studies (GWAS) and "next-generation" whole genome DNA sequencing using samples from large numbers of patients treated with a specific anticancer or antidepressant drug. Sophisticated cell-based functional genomic techniques are used to determine mechanisms responsible for variation in drug response phenotypes. This approach has already succeeded in the discovery and functional/mechanistic pursuit of novel, unanticipated genes that influence response to a series of drugs used to treat childhood leukemia and breast cancer. Dr. Weinshilboum's research has been continuously funded for decades by the National Institutes of Health and other Foundation funding mechanisms.
Research Interest
Nephrology and Hypertension Research Center for Clinical and Translational Science (CCaTS) Epidemiology and Genetics of Lung Cancer Research Program Experimental Therapeutics Program Women's Health Research Center Molecular Pharmacology and Experimental Therapeutics Research Mayo Clinic Cancer Center — Research Center for Individualized Medicine Pharmacogenomics - Richard M. Weinshilboum Aging: Robert and Arlene Kogod Center on Aging Women's Cancer Program
Biography
Wael k. Ali is affiliated to General Secretary of EMROpharm forum-international pharmaceutical federation (FIP) and President of Egyptian organization of pharmacy, Egypt.
Research Interest
Wael k. Ali is a recipient of many awards and grants for his valuable contributions and discoveries in major area of subject research. His international experience includes various programs, contributions and participation in different countries for diverse fields of study.
Biography
he research of Liewei Wang, M.D., Ph.D., is focused on pharmacogenomics, a critical component of individualized medicine that studies the role of inheritance in variation in drug response. Patients treated with the same dose or regimen of a drug can display different responses, ranging from lack of efficacy to severe toxicity. Dr. Wang's laboratory uses various high-throughput "omics" tools, including genomics, transcriptomics and metabolomics, to identify biomarkers that can help predict clinical response. At the same time, her lab uses various models, including cells, patient-derived xenografts and patient samples, to validate and understand the biology underlying these biomarkers.
Research Interest
Molecular Pharmacology and Experimental Therapeutics Research Pharmacogenomics and Drug Targets - Liewei Wang Center for Individualized Medicine Epidemiology and Genetics of Lung Cancer Research Program Experimental Therapeutics Program Women's Health Research Center Mayo Clinic Cancer Center — Research Women's Cancer Program